Table I.
Adverse Events
HBsAg + ABX196 | ||||||
---|---|---|---|---|---|---|
HBsAg n = 7 |
Heberbiovac n = 8 |
HBsAg + ABX196 0.2 µg n = 6 |
HBsAg + ABX196 0.4 µg n = 11 |
HBsAg + ABX196 2 µg n = 12 |
||
TEAE | Number | 24 | 18 | 26 | 115 | 110 |
% Subjects | 85.7% | 87.5% | 66.7% | 100.0% | 100.0% | |
Moderate and Severe TEAE | Number | 8 | 1 | 10 | 36 | 37 |
% Subjects | 42.9% | 12.5% | 33.3% | 90.9% | 91.7% |
TEAE: Treatment Emergent Adverse Event